BR112015031196A2 - “processo de purificação de anticorpo monoclonal” - Google Patents

“processo de purificação de anticorpo monoclonal”

Info

Publication number
BR112015031196A2
BR112015031196A2 BR112015031196A BR112015031196A BR112015031196A2 BR 112015031196 A2 BR112015031196 A2 BR 112015031196A2 BR 112015031196 A BR112015031196 A BR 112015031196A BR 112015031196 A BR112015031196 A BR 112015031196A BR 112015031196 A2 BR112015031196 A2 BR 112015031196A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
purification process
antibody purification
provides
desired monoclonal
Prior art date
Application number
BR112015031196A
Other languages
English (en)
Inventor
Kumar Singh Avanish
Bandyopadhyay Sanjay
Kumar Mendiratta Sanjeev
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015031196(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of BR112015031196A2 publication Critical patent/BR112015031196A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)

Abstract

a presente invenção proporciona um método aprimorado para a purificação de anticorpo monoclonal a partir de cultura de célula. processo de purificação do anticorpo monoclonal desejado compreende cromatografia de afinidade, interação hidrófoba e opcionalmente cromatografia de coluna de troca de íon. a mesma proporciona mais do que 99% de pureza do anticorpo monoclonal desejado.
BR112015031196A 2013-06-25 2014-06-25 “processo de purificação de anticorpo monoclonal” BR112015031196A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2014/000421 WO2014207763A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
IN2145MU2013 IN2013MU02145A (pt) 2013-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
BR112015031196A2 true BR112015031196A2 (pt) 2017-07-25

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031196A BR112015031196A2 (pt) 2013-06-25 2014-06-25 “processo de purificação de anticorpo monoclonal”

Country Status (19)

Country Link
US (1) US9708365B2 (pt)
EP (1) EP3013849B1 (pt)
JP (1) JP6039828B2 (pt)
KR (1) KR101683415B1 (pt)
CN (1) CN105263947A (pt)
AR (1) AR096713A1 (pt)
AU (1) AU2014300486B2 (pt)
BR (1) BR112015031196A2 (pt)
CA (1) CA2911874A1 (pt)
EA (1) EA201592192A1 (pt)
HK (1) HK1217344A1 (pt)
IL (1) IL242649A (pt)
IN (1) IN2013MU02145A (pt)
MX (1) MX350610B (pt)
NZ (1) NZ714079A (pt)
SG (1) SG11201509502XA (pt)
TW (1) TWI596107B (pt)
WO (1) WO2014207763A1 (pt)
ZA (1) ZA201508258B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
CA2978095C (en) * 2015-03-13 2022-02-15 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
JP7073253B2 (ja) 2015-08-21 2022-05-23 エフ．ホフマン－ラ ロシュ アーゲー アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
BR112018001511A2 (pt) * 2015-08-21 2018-09-18 Hoffmann La Roche ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CN109641050A (zh) 2016-08-16 2019-04-16 里珍纳龙药品有限公司 用于对混合物中的个体抗体进行量化的方法
CN109923411B (zh) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
AU2017347809A1 (en) * 2016-10-28 2019-05-09 Merck Sharp & Dohme Llc Purification process for removal of tyrosine sulfation antibody variants; purified compositions
WO2018116198A1 (en) 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
KR102087823B1 (ko) * 2017-05-16 2020-03-13 에이치케이이노엔 주식회사 친화성 크로마토그래피를 이용한 항체 또는 항체절편 정제 방법
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020016417A1 (en) * 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN111153993A (zh) * 2018-11-07 2020-05-15 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
EP4061825A1 (en) 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography
CN114929725A (zh) * 2020-01-08 2022-08-19 信达生物制药(苏州)有限公司 阿达木单抗纯化方法及其稳定组合物
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (en) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Protein purification by affinity chromatography
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (en) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Resin and chromatography column that purifies antibodies with protease resistant small peptides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
EP1308456B1 (en) 1998-05-06 2007-08-22 Genentech, Inc. Antibody purification by ion exchange chromatography
JP2002517406A (ja) * 1998-06-01 2002-06-18 ジェネンテック・インコーポレーテッド イオン交換クロマトグラフィーの使用による、凝集体からのタンパク質モノマーの分離
EP1614693A4 (en) 2003-03-31 2006-07-19 Kirin Brewery PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
AU2006259298B2 (en) 2005-06-17 2012-06-14 Wyeth Llc Methods of purifying Fc region containing proteins
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
EP2004689A4 (en) 2006-04-05 2010-06-02 Abbott Biotech Ltd PURIFICATION OF ANTIBODIES
CL2007002615A1 (es) 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
WO2010030222A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
EP2491055A2 (en) 2009-10-20 2012-08-29 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
EP2695889A1 (en) * 2009-12-29 2014-02-12 Dr. Reddy's Laboratories Limited Protein purification by ion exchange
DK2526114T3 (da) 2010-01-22 2014-09-29 Boehringer Ingelheim Int Kromatografisk fremgangsmåde til oprensning af FC-indeholdende proteiner
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
TW201221641A (en) * 2010-10-11 2012-06-01 Abbott Lab Processes for purification of proteins
EP3578522A1 (en) 2010-12-06 2019-12-11 Pall Corporation Continuous processing methods for biological products
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
WO2014159441A1 (en) * 2013-03-14 2014-10-02 Amgen Inc. Removal of leaked affinity purification ligand
AU2014303125A1 (en) * 2013-05-13 2015-11-12 Medimmune, Llc Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales

Also Published As

Publication number Publication date
JP2016525500A (ja) 2016-08-25
WO2014207763A1 (en) 2014-12-31
AU2014300486B2 (en) 2016-06-30
MX2015016586A (es) 2016-03-16
JP6039828B2 (ja) 2016-12-07
TWI596107B (zh) 2017-08-21
CA2911874A1 (en) 2014-12-31
AU2014300486A1 (en) 2015-11-26
IL242649A (en) 2016-03-31
MX350610B (es) 2017-09-11
KR20160003311A (ko) 2016-01-08
IN2013MU02145A (pt) 2015-06-05
US20160115195A1 (en) 2016-04-28
EP3013849B1 (en) 2017-09-13
ZA201508258B (en) 2017-03-29
CN105263947A (zh) 2016-01-20
NZ714079A (en) 2017-05-26
US9708365B2 (en) 2017-07-18
EA201592192A1 (ru) 2016-07-29
HK1217344A1 (zh) 2017-01-06
KR101683415B1 (ko) 2016-12-06
TW201512217A (zh) 2015-04-01
SG11201509502XA (en) 2015-12-30
EP3013849A1 (en) 2016-05-04
AR096713A1 (es) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112015031196A2 (pt) “processo de purificação de anticorpo monoclonal”
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
WO2011106750A3 (en) Method and apparatus for enhanced lifetime and performance of ion source in an ion implantation system
BR112014010955A2 (pt) sistema e método para processar amostras
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112013000623A2 (pt) purificação de proteína.
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
BR112017024243A2 (pt) Sal de (s)-csa de s-cetamina, sal de (r)-csa de s- cetamina e processos para a preparação de s- cetamina
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
BR112012024956A2 (pt) processo para a purificação de uma proteína de fator de crescimento
MX2016007297A (es) Proceso para purificar 2,5-diclorofenol.
BR112013005152A2 (pt) sistema de controle de separação eletrostática
BR112018075667A2 (pt) cromatografia de interação hidrofóbica para purificação de oligonucleotídeos
BR112016023680A2 (pt) ?processo de purificação de gonadotropina?
BR112018016742A2 (pt) purificação de proteína
AR103172A1 (es) Reducción selectiva de residuos de cisteina en anticuerpos il-17
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
TR201902152T4 (tr) Metiltioninyum klorür (mtc) bulunan diaminofenotiazinyum bileşiklerinin kimyasal sentezi için yöntemler.
BR112013007478A2 (pt) método de separação de separar (a) e (b)
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2625 DE 27-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.